Dry swabs can be successfully used to detect drugs on smartphone surfaces, study shows. A simple and convenient method to collect drug use data from the surface of a smartphone is revealed for the first time in a new study published in De Gruyter’s Clinical Chemistry and Laboratory Medicine. By helping clinicians understand what drugs people are taking in certain contexts, the research could protect public health and improve the treatment of patients suspected of overdosing. Dr. Théo Willeman of Grenoble Alpes University Hospital, France and colleagues explored whether one of our most handled objects – the smartphone – could be a more convenient way to track drug use. Fingerprints on a phone’s surface contain sweat and sebum that can reveal the presence of drugs, and the surface itself can retain traces of any drugs consumed directly from it. The… 

Künstliche Intelligenz hilft bei der Diagnose: Was ist der Grund für eine Entzündung und wie lässt sie sich bekämpfen? Eine neue Anwendung künstlicher Intelligenz (KI) unterscheidet Infektionen nach ihrer Verursachung durch Bakterien, Viren oder andere Faktoren. Ein Forschungsteam der Philipps-Universität Marburg berichtet im Fachblatt „Frontiers in Immunology“ über das selbstentwickelte Verfahren. Die Autorinnen und Autoren der Studie nutzten eine Kombination einfacher Bluttests und entwickelten eine KI, die zwischen bakteriellen Infektionen, viralen Virusinfektionen und Autoimmunerkrankungen unterscheiden kann. Die Forschungsgruppe analysierte Blut von 80 Patientinnen und Patienten mit entzündlichen Erkrankungen und verglich die Ergebnisse mit denen von 38 Kontrollpersonen ohne Entzündung. Aufgrund der Blutproben konnte eine zweistufige KI-Anwendung diese beiden Gruppen auseinanderhalten. Die Künstliche Intelligenz unterscheidet außerdem zwischen verschiedenen Arten von Entzündungen“, berichtet Thrun: Bakterielle Infektionen, Virusinfektionen und Autoimmunerkrankungen werden mit einer Genauigkeit von 90,3 Prozent, 80,0 bzw. 79,0 Prozent erkannt. „Sobald… 

Hyundai Bioscience (KOSDAQ 048410) announced the positive results from its preclinical study on triple-negative breast cancer, investigating combination therapy of ‚Niclosamide-based oral anti-cancer drug‘ jointly developed with CNPharm and Docetaxel, one of widely-used chemical anticancer agents. As a result, the combination therapy was found to be more effective than Docetaxel alone. The anti-cancer efficacy of the combination therapy group was 67% better than the Docetaxel-treated group. From the in vitro test, Niclosamide successfully inhibited the proliferation and survival of cancer cells by disrupting their metabolism, preventing the anticancer drug-resistance by blocking the cell signaling pathways of tumor cells and recurrence and metastasis of cancer by inhibiting cancer stem cells. Niclosamide is found to be an antitumor agent that blocks metabolism, and Niclosamide-based anticancer drugs can solve the resistance and metastasis problems simultaneously. Due to its anticancer mechanism, Niclosamide is effective… 

German Chancellor Olaf Scholz, accompanied by Norwegian Prime Minister Jonas Gahr Støre, learnt about the innovations of the Stuttgart-based global market leader for integrated solutions and branded products in the field of cable and connection technology. Matthias Lapp, CEO of the Lapp Group, presented the first ETHERLINE® FD bioP Cat.5e data cable, which consists of a partially bio-based sheath material based on corn, to the Federal Chancellor as a highlight. The special thing about it is that previous data cables only had cable sheaths made of plastic. The new, sustainable version with a bio-based outer sheath consists of 43 per cent renewable raw materials. This reduces the carbon footprint by 24 per cent compared to the fossil-based jacket. Matthias Lapp presented the organic version of the cable to the two politicians. „Feel it, this is what an organic sheath feels… 

Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs). The ability to recreate these cells in an iPSC-based model will allow researchers to analyze the historically difficult to isolate cells in greater detail, helping to further the understanding of human lung regeneration and may ultimately expedite progress in treatment and therapeutic options for people living with pulmonary diseases. The results of this study provide an in vitro model of human AT1 cells, which line the vast majority of the gas exchange barrier of the distal lung, and are a potential source of human AT1s to develop regenerative therapies. This new study also furthers the CReM’s goal… 

Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs). The ability to recreate these cells in an iPSC-based model will allow researchers to analyze the historically difficult to isolate cells in greater detail, helping to further the understanding of human lung regeneration and may ultimately expedite progress in treatment and therapeutic options for people living with pulmonary diseases. The results of this study provide an in vitro model of human AT1 cells, which line the vast majority of the gas exchange barrier of the distal lung, and are a potential source of human AT1s to develop regenerative therapies. This new study also furthers the CReM’s goal… 

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) („NeuroSense“), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s state-of-the-art technology that derives frontal cortex neurons from individual patients‘ blood to quantify drug-induced neuronal plasticity in vitro. Distinguished by its innovative approach, NeuroSense’s PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (A?), PrimeC adopts a multi-targeted strategy, concurrently addressing A? aggregation, TDP-43, and other key disease-related pathologies. This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) („NeuroSense“), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s state-of-the-art technology that derives frontal cortex neurons from individual patients‘ blood to quantify drug-induced neuronal plasticity in vitro. Distinguished by its innovative approach, NeuroSense’s PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (A?), PrimeC adopts a multi-targeted strategy, concurrently addressing A? aggregation, TDP-43, and other key disease-related pathologies. This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes.

Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival through early detection, today?announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study.  In the study, Immunovia’s next-generation test demonstrated specificity of 98 percent and sensitivity of 75 percent in detecting early stage (1 and 2) pancreatic ductal adenocarcinoma (PDAC), a very aggressive and the most common form of pancreatic cancer. The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.  Importantly, these results confirm the technical advancement of the next-generation test over Immunovia’s first-generation test, IMMray PanCan-d. The next-generation test includes high-performing protein biomarkers, making the test less reliant on CA19-9. This is a major achievement as around 10 percent of patients, including many patients of African ancestry, do…